Rapid Matched-Pair VHH Antibody Discovery for Clinical-Stage Vaccine Characterization

Background

A leading global vaccine development company reached a critical juncture in its clinical-stage vaccine program. To ensure the success of their active clinical trials, they required high-quality matched-pair recombinant antibodies for advanced analytical assay development and comprehensive vaccine characterization. The project demanded antibodies capable of recognizing distinct, non-overlapping epitopes to facilitate reliable quantification and stability testing of the vaccine antigen.

Key Challenges

• Epitope Mapping Complexity: The antibodies needed to target different, non-competing epitopes to function as a matched pair in sandwich-based analytical formats.
• Aggressive Timelines: With active clinical trials underway, any delay in assay development threatened the entire regulatory submission schedule.
• Assay Compatibility: There was a significant lack of commercially available antibodies compatible with the client’s specific clinical assay formats.

Our Approach

• Yashraj Biotechnology Ltd. (YBL) deployed its synthetic VHH antibody library platform to accelerate the discovery and engineering process.
• Rapid Discovery Workflow: We utilized our diverse VHH library to bypass the months-long immunization phase required by traditional animal-based methods.
• Strategic Epitope Screening: Through an optimized screening workflow, we prioritized the identification of binders that targeted distinct regions of the antigen.
• Validation for Analytical Assays: Lead candidates were rapidly validated in matched-pair configurations (Capture vs. Detection) to ensure high sensitivity and zero competition for the same epitope.

Results

The efficiency of the YBL-Vega platform allowed for an end-to-end delivery that far exceeded industry standard timelines.

• High-Affinity Binders: Successfully identified multiple high-affinity VHH binders targeting non-overlapping epitopes.
• 10-Week Delivery: The entire discovery, screening, and validation program was completed within 10 weeks, providing the client with application-ready reagents.
• Seamless Integration: The validated pairs were immediately integrated into the client’s vaccine characterization and clinical trial workflows.

Key Insight